[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-carcinoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,50,83,117,156,180,213,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100614772","studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays-100614772",false,"NCT07283939","Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays","PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays","Inclusion Criteria:\n\n* \\* REGISTRATION ELIGIBILITY CRITERIA (STEP 1)\n\n  * Histologic confirmation of invasive cancer that is confirmed or suspected to arise from the gastrointestinal (GI) tract\n  * Any stage for which FOLFOX-based chemotherapy is a clinically-indicated, standard-of-care treatment (adjuvant, neoadjuvant, or first-line chemotherapy)\n  * Eligible primary tumor sites include the esophagus, gastroesophageal junction, stomach, small intestine, ampulla of Vater, appendix, colon, rectum, and cancers of unknown primary with suspected GI origin\n  * Prior systemic therapy for GI cancer (other than cycle 1 of FOLFOX-based chemotherapy) is not allowed. Prior radiation-sensitizing chemotherapy is permitted\n  * The planned duration of FOLFOX-based chemotherapy must be at least four cycles (1 cycle = 14 days)\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must be completed 1 to 8 days prior to registration\n  * Cycle 1, day 1 of FOLFOX-based chemotherapy must include minimum ordered doses of oxaliplatin (≥ 65 mg\u002Fm\\^2) and infusional 5-FU (2400 mg\u002Fm\\^2\u002F46 hours). Use of the 5-FU bolus is at the discretion of the treating physician\n  * Patients who require primary prophylactic white blood cell growth factor with cycle 1 of FOLFOX chemotherapy due to high risk for fever and neutropenia are not eligible\n  * History of hypersensitivity reaction to oxaliplatin or other platinum-based drugs, to fluorouracil, or to leucovorin, and the excipients in their formulations are not eligible\n  * Age ≥ 18 years\n  * ECOG performance status ≤ 2\n  * Absolute neutrophil count (ANC) ≥ 1,000\u002Fmm\\^3\n  * Platelet count ≥ 100,000\u002Fmm\\^3\n  * Total bilirubin ≤ 3 x upper limit of normal (ULN)\n  * AST (SGOT)\u002FALT (SGPT) ≤ 5 x upper limit of normal (ULN)\n  * Calc. creatinine clearance ≥ 30 mL\u002Fmin\n  * Not pregnant and not nursing, because this study involves agents that have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 30 days prior to registration is required\n  * Patients with treated brain metastases are eligible if follow-up brain imaging after CNS-directed therapy shows no evidence of progression\n  * Patients with known HIV infection are eligible if receiving effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration\n  * Patients with known chronic hepatitis B virus (HBV) infection are eligible if HBV DNA is undetectable when measured within 6 months prior to registration\n  * Patients with a known history of hepatitis C virus (HCV) infection are eligible if HCV RNA is undetectable when measured at least 12 weeks after completion of antiviral therapy\n  * Patients with known history or current symptoms of cardiac disease are eligible if the New York Heart Association Functional Classification is class I or II\n  * Patients with a known history of congenital long QT syndrome are ineligible\n  * Patients with known DPD deficiency are ineligible\n* \\* NON-PATIENT (ONCOLOGY PHYSICIAN OR ONCOLOGY ADVANCED PRACTICE PROVIDER ELIGIBILITY:\n\n  * The non-patient provider participant is a medical oncologist or oncology advanced practice provider with responsibility for signing and making necessary modifications to chemotherapy orders for a subject assigned to the intervention arm (Arm B). Non-patient participants may not be enrolled more than once over the course of the study\n  * The non-patient participant must be proficient in the English language\n  * The non-patient participant must be age 21 years or older",true,"ALL","18 Years",{"count":20,"type":21},420,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.",[27,28,29,30,31,32,33,34,35,36],"Ampulla of Vater Carcinoma","Appendix Carcinoma","Carcinoma of Unknown Primary With Gastrointestinal Profile","Colon Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Gastroesophageal Junction Carcinoma","Malignant Digestive System Neoplasm","Rectal Carcinoma","Small Intestinal Carcinoma","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2026-02-13",{"date":45,"type":21},"2030-05-02",{"name":47,"class":48},"Alliance for Clinical Trials in Oncology","OTHER",344,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100624118","phase-2-zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment-100624118","NCT07405476","Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed colon and\u002For rectal cancer planned for curative intent treatment at gastrointestinal clinics of Emory University's Winship Cancer Institute and collaborating centers\n* Tumors must be HER2+ve (human epidermal growth factor receptor 2 \\[HER2\\] overexpression 3+ immunohistochemistry \\[IHC\\] or 2+ by IHC and positive fluorescence in situ hybridization \\[FISH\\] or HER2 amplification by next generation sequencing)\n* Tumors must have RAS wildtype genotype\n* Radiologically measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Age ≥ 18 years\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 50%)\n* Platelet count \\> 100,000 cells\u002F ul (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Hemoglobin \\> 9g\u002Fdl (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Absolute neutrophil count \\> 1000 cells\u002Fdl (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN) (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Alanine aminotransferase (ALT) ≤ 3 × ULN (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Total bilirubin ≤ 1.5 × ULN, or ≤ 3 × ULN for participants with Gilbert's disease (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Glomerular filtration rate (GFR) \\> 60ml\u002Fmin (based on creatine, and Cystatin C estimation where applicable) (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Adequate cardiac function with left ventricular ejection fraction of at least 50% (within 28 days of cycle 1 day 1, at the discretion of the investigator)\n* Females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy\n* FCBP and men treated or enrolled on this protocol must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and 3 months after completion of study drug administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n\n  \\* A female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Willingness and ability of the subject to comply with scheduled visits, drug administration plan, protocol-specified laboratory tests, other study procedures, and study restrictions. This includes willingness to undergo mandatory blood sample draws for evaluation of correlatives\n* Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n* Participants with stage IV colon and rectal cancer even if curative intent resection is planned\n* HER2 expression that does not meet documented inclusion criteria\n* RAS mutation\n* MSI-H or mismatch repair deficient rectal cancer\n* Clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension or any history of symptomatic congestive heart failure (CHF). Participants with known myocardial infarction or unstable angina within 6 months prior to expected date of cycle 1 day 1 (C1D1) are also excluded. Previous anticancer therapy-related CHF must have been ≤ grade 1 at the time of occurrence and must have completely resolved\n* Participants receiving any other investigational agents or an investigational device within 28 days of administering the first dose of study drug\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in study\n* Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.",{"count":58,"type":21},38,[60],"PHASE2","This phase II trial studies how well giving zanidatamab before surgery (neoadjuvant) works in treating patients with colon and rectal cancer that is human epidermal growth factor receptor 2 positive (HER2+ve) who are planned for curative intent treatment. Zanidatamab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).",[30,63,35,64,65,66,67,68,69,70,71,72],"Colorectal Carcinoma","Stage I Colon Cancer AJCC v8","Stage I Colorectal Cancer AJCC v8","Stage I Rectal Cancer AJCC v8","Stage II Colon Cancer AJCC v8","Stage II Colorectal Cancer AJCC v8","Stage II Rectal Cancer AJCC v8","Stage III Colon Cancer AJCC v8","Stage III Colorectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","2026-04-16",{"date":75,"type":41},"2026-04-17",{"date":77,"type":41},"2026-04-07",{"date":79,"type":21},"2029-12-18",{"name":81,"class":48},"Emory University",4,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100287781","phase-2-neoadjuvant-immune-checkpoint-inhibition-and-novel-io-combinations-in-early-stage-colon-cancer-100287781","NCT03026140","Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)","NICHE","Inclusion criteria:\n\n* Signed written informed consent\n* Patients at least 18 years of age\n* Non-metastatic adenocarcinoma of the colon (and rectosigmoid considered as nonrectal and not undergoing neoadjuvant treatment)\n\n  * No signs of distant metastases on CT-scan and physical examination;\n  * dMMR cohorts 3+6: \\>cT3 and\u002For N+\n\nExclusion criteria:\n\n* No signs of distant metastases\n* No signs of obstruction or macroscopic bleeding or suspicion of perforation\n* Colonoscopy must be performed after registration to obtain study-specific biopsies. If biopsies are not possible, patients cannot be included in the study\n* WHO performance status of 0 or 1\n* No previous treatment with immune checkpoint inhibitors targeting CTLA-4, PD-1 or PD-L1\n* For patients with MSS tumors: no current use of NSAIDs or COX2-inhibitors at registration and no active peptic ulcer, gastrointestinal bleeding, unstable ischemic heart disease of thrombus etiology or significant established ischemic heart disease, peripheral arterial disease and\u002For cerebrovascular disease\n* No radiotherapy prior to or planned post-surgery radiotherapy\n* No history of allergy to study drug components, severe hypersensitivity reaction to any monoclonal antibody, allergy or severe hypersensitivity to NSAIDs or COX2-I (MSS tumors)\n* No intercurrent illnesses, including but not limited to infections, unstable angina pectoris\n* No positive test for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection\n* No autoimmune disease\n* No conditions requiring systemic treatment with either corticosteroids (10 mg daily prednisone or more and equivalents) or other immunosuppressive medications within 14 days of study drug administration\n* No live vaccines in the 4 weeks prior to inclusion",{"count":92,"type":21},353,[60],"In this exploratory study, patients with stage 1-3 adenocarcinoma of the colon with no signs of distant metastases will be treated with short-term immunotherapy + novel IO combinations (i.e. anti-IL 8, COX2-inhibitors, anti-LAG3). This treatment will be given during the window period until surgical resection of the tumor. The duration of treatment will be in between approximately 6 and 12 weeks.",[30],[97,98,99,100,101,102,103,104,105,106],"MSI tumors","MSS tumors","short-term immunotherapy","surgical resection","nivolumab","ipilimumab","COX2","Anti-IL8","Relatlimab","Anti-LAG3","2026-03-03",{"date":109,"type":41},"2026-03-05",{"date":111,"type":41},"2017-03-29",{"date":113,"type":21},"2032-03-01",{"name":115,"class":48},"The Netherlands Cancer Institute",6,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":141,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":155},"100565717","early-phase-1-pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors-100565717","NCT06645808","PET-imaging of Two Vartumabs in Patients With Solid Tumors","The Safety, Tolerability and Biodistribution of a Single Intravenous Administration of Two Zirconium-89 Labelled Vartumabs (F8scFV or C9scFv) in Patients With Solid Tumors - a Phase 0, Open Label, PET\u002FCT Molecular Imaging Basket Trial","VARTUTRACE","General Inclusion Criteria:\n\n1. Willing to adhere to the prohibitions and restrictions specified in this protocol.\n2. Capable of giving signed informed consent (voluntarily), indicating that the patient understands the purpose and procedures required for the study and is willing to comply with the requirements and restrictions listed in the informed consent form and in this protocol.\n3. Patients aged ≥ 18 years at moment of signing informed consent form.\n4. Life expectancy of \\> 12 weeks.\n5. ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.\n6. BMI ≥ 18.0 and ≤ 35.0 kg\u002Fm2 and weight at least 50 kg and no more than 120 kg at screening.\n7. Overtly healthy based on medical history, physical findings, vital signs, ECG at the time of screening, as judged by the Investigator. Note: one retest of vital functions and ECG is allowed within the screening window.\n8. Adequate liver- and kidney function, defined by the following laboratory results obtained during screening visit:\n\n   * AST, ALT, and alkaline phosphatase ≤ 2.5x the upper limit of normal (ULN) as determined by the UMCG laboratory reference values.\n   * Serum bilirubin ≤ 2.0x ULN as determined by the UMCG laboratory reference values. Patients with known Gilbert disease who have serum bilirubin level ≤ 3x ULN may be enrolled.\n   * INR or APTT ≤ 1.5x ULN as determined by the UMCG laboratory reference values. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.\n   * eGFR (based on plasma-creatinine) = \\>30 mL\u002Fmin.\n   * Serum albumin \\>35 g\u002FL.\n9. No other clinically significant laboratory abnormalities as determined by the investigator. Note: one retest of lab tests is allowed within the screening window.\n10. Female patients should be at least 1 year post-menopausal (amenorrhea \\>12 months and\u002For follicle-stimulating hormone \\>30 mIU\u002FmL) at screening or surgically sterile (bilateral oophorectomy, hysterectomy, or tubal ligation).\n11. Male subjects who are sexually active with a female partner of childbearing potential must agree to the use of an effective method of birth control, and must not donate sperm, until 3 months after administration of 89Zr-DFO-N-Suc-scFv (F8 or C9).\n\nMedical inclusion Criteria:\n\nColon Carcinoma:\n\n1. Patients diagnosed with colon carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of colon carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nRectal Carcinoma:\n\n1. Patients diagnosed with rectal carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of rectal carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBone- and soft-tissue sarcoma\n\n1. Patients diagnosed with a bone- or soft-tissue sarcoma stage I-IV, according to AJCC staging for Sarcoma.\n2. Histologically confirmed diagnosis of sarcoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBreast carcinoma\n\n1. Patients diagnosed with breast carcinoma stage I-IV, according to the 8th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of breast carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nLung Carcinoma:\n\n1. Anticipated diagnosis of Non-Small Cell Lung Carcinoma (NSCLC) stage I-IV, according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)\u002FCT or based on cytology.\n2. Neo-adjuvant treatment according to the standard of care.\n\nHead and Neck Squamous Cell carcinoma (HNSCC):\n\n1. Patients diagnosed with HNSCC of the oral cavity, oropharynx, nasal cavity, nasopharynx, hypopharynx and larynx.\n2. Histologically confirmed diagnosis of HNSCC.\n3. Neo-adjuvant treatment according to the standard of care.\n\nOesophageal and gastric carcinoma:\n\n1. Patients diagnosed with oesophagus carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n2. Patients diagnosed with gastric carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n3. Histologically confirmed diagnosis of oesophageal- or gastric carcinoma.\n4. Neo-adjuvant treatment according to the standard of care.\n\nPancreas carcinoma:\n\n1. Anticipated diagnosis of pancreas carcinoma stage I-IV according to the 8th edition of the TNM-classification, based on imaging modalities such as (PET)\u002FCT or based on cytology.\n2. Histologically or cytologically confirmed diagnosis of pancreas carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nBladder carcinoma:\n\n1. Patients diagnosed with invasive bladder carcinoma stage I-IV according to the 7th edition of the TNM-classification.\n2. Histologically confirmed diagnosis of bladder carcinoma.\n3. Neo-adjuvant treatment according to the standard of care.\n\nGlioblastoma:\n\n1. Anticipated diagnosis of a high-grade glioma (glioblastoma, grade 4 according to the WHO classification) based on imaging modalities such as MRI and\u002For CT or a biopsy.\n2. Karnofsky performance status of at least 70%.\n3. Neo-adjuvant treatment according to the standard of care.\n\nGeneral Exclusion Criteria:\n\n1. Behavioral or cognitive impairment or psychiatric disease that, in the investigator's opinion, affects the patient's ability to understand and cooperate with the study protocol.\n2. Insufficient venous access for the study procedures.\n3. Close affiliation with the investigator, e.g. a close relative of the investigator, dependent person (e.g. employee or student), employee of the department of surgery or nuclear department of the UMCG,TRACER or affiliates.\n4. Any finding in the medical examinations or medical history giving, in the opinion of the investigator, reasonable suspicion of a disease or condition that makes treatment with the investigational drug unadvisable, or that might affect interpretation of the results of the study or render the patient at high risk for treatment complications.\n5. Participation in an interventional clinical study within 30 days prior to tracer administration that involved treatment with any drug (excluding vitamins and minerals) or medical device.\n\nMedical Exclusion Criteria:\n\n1. The existence of a second concomitant active malignancy or treatment for a second malignancy within 1 year prior to IMP-administration that is not a solid tumor indication included in the VARTUTRACE study, except for localized basal or squamous cell cancer that has been cured at least 90 days before screening.\n2. Cardiac impairment with an estimated LVEF \\\u003C35 % Prolonged QTcF (\\>450 ms), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the investigator.\n3. Any abnormalities in the vital signs of the patient, as judged by the investigator, as a result of which the patient cannot participate. Note: One retest of vital functions is allowed within the screening window.\n4. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.\n5. Major surgical procedure other than for the included diagnosis within four weeks before IMP administration. Disease-related procedures, e.g. the placement of a port-a-cath, placement of a drain, ERCP, are allowed.\n6. Current evidence or history of bacterial, viral or fungal infections within 7 days before 89Zr-DFON-Suc-scFv (F8 or C9) administration as judged by the Investigator.\n\n   * T \\> 38.0°C or lab confirmed viral\u002Fbacterial\u002Ffungal infection (PCR) or symptoms suggestive of an infection)\n   * Received oral or IV antibiotics within \\\u003C7 days before administration.\n7. Any planned major surgery within the duration of the study (until follow-up visit) that is not related to the tumor, with the exception of any emergency surgeries.\n8. Prior allogeneic bone marrow transplantation or solid organ transplant.\n9. A history of anaphylaxis, history of allergic reaction(s), known allergy to one of the drugs or excipients administered as part of this study. Mild allergies without angio-edema or treatment need can be acceptable if deemed not of clinical significance (including allergy to animals or mild seasonal hay fever).\n10. Any other diseases, metabolic dysfunction, physical examination finding, or clinically significant laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications.",{"count":126,"type":21},32,[128],"EARLY_PHASE1","VARTUTRACE is a first-in-human PET\u002FCT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).\n\nOncofetal CS are tumor-specific carbohydrate motifs present in proteoglycans and identified by VAR2 Pharmaceuticals as expressed during fetal development. Oncofetal CS reappears in the vast majority of cancers while remaining largely absent from normal tissues.\n\nVAR2 Pharmaceuticals recently developed antibodies specific for oncofetal CS. VARTUTRACE uses two of these as radiolabeled antibody fragments to study biodistribution, tumor accumulation, pharmacodynamics and clearance pathways in a diverse patient population.",[131,30,35,132,133,134,135,31,32,136,137,138,139,140],"Solid Tumor","Osteosarcoma","Chondrosarcoma","Lung Carcinoma","Head and Neck Squamous Cell Carcinoma","Pancreas Carcinoma","Bladder Carcinoma","Glioblastoma","Soft Tissue Sarcoma (STS)","Breast Cancer",[142,143,144],"Basket-trial","Oncology","Solid tumors","2025-12-19",{"date":147,"type":41},"2025-12-29",{"date":149,"type":41},"2024-12-10",{"date":151,"type":21},"2026-09",{"name":153,"class":154},"Var2 Pharmaceuticals","INDUSTRY",1,{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":4,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100572332","phase-2-phytocannabinoids-for-reducing-chronic-chemotherapy-induced-peripheral-neuropathy-in-breast-and-colon-cancer-survivors-100572332","NCT06731894","Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors","A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Documented informed consent of the participant and\u002For legally authorized representative.\n\n  * Assent, when appropriate, will be obtained per institutional guidelines\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval\n* Willingness to comply with all study interventions including the use of medical cannabis and follow-up assessments\n* Age: ≥ 18 years\n* Eastern Cooperative Oncology Group Performance Status Scale (ECOG) score ≤ 2\n* Ability to read and understand English for questionnaires\n* Patients must have either neuropathy ≥ 1 according to Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 scale or a neuropathy score of \\> 3 on a 0-10 scale plus a FACT\u002FGOG-Ntx score of \\> 10\n* The patient's previous chemotherapy treatment must have included a taxane (paclitaxel, nab-paclitaxel, or docetaxel) or platinum (cisplatin, oxaliplatin, or carboplatin) and considered the primary cause of the neuropathy by the medical team\n* Total bilirubin ≤ 1.5 X upper limits of normal (ULN) (unless has Gilbert's disease) (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n* Aspartate aminotransferase (AST) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n* Alanine aminotransferase (ALT) ≤ 3 x ULN (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required (To be performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)\n* Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 1 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only)\n\nExclusion Criteria:\n\n* Current active treatment with chemotherapy, radiation or surgery in the past 3 months or planned treatment during this study protocol period. Note: Hormonal therapy is allowed\n* Treatment with any neuropathic agent including taxane, platinum, vinca alkaloid, or bortezomib chemotherapy within the past 6 months\n* Concurrent use of other alternative medicines such as medical cannabis, herbal agents and high dose vitamins and minerals\n* Liver cirrhosis Child-Pugh B or C\n* Mental incapacitation or significant emotional or psychological disorder that, in the opinion of the investigators, precludes study entry. (These patients may not be able to cooperate with this slightly invasive procedure or with the data collection process.)\n* History of diabetic neuropathy, neuropathy related to HIV, or other medical causes of chronic neuropathy in the baseline assessment including past medical history, any history of diabetes, alcoholism, and vitamin B deficiency\n* Previous medical cannabis use for any indication within 30 days of enrollment\n* Planned or actual changes in type of medications that could affect symptoms related to CIPN. New medications for the treatment of CIPN are not allowed during the study.\n\n  * Subjects need to be on stable doses of CIPN medications for 4 weeks\n* Strong inhibitors or inducers of CYP3A4\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Clinically significant uncontrolled illness\n* Diagnosis of Gilbert's disease\n* Females only: Pregnant or breastfeeding\n* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics)\n* Patients who have an allergy or an aversion to strawberry or strawberry flavoring",{"count":164,"type":21},120,[60],"This phase II trials evaluates how well different types of phytocannabinoids (cannabidiol \\[CBD\\] versus tetrahydrocannabinol \\[THC\\] and CBD formulation \\[THC:CBD\\]) work to reduce chronic chemotherapy-induced peripheral neuropathy among breast and colon cancer survivors. Chemotherapy induced peripheral neuropathy is a set of symptoms that includes pain, tingling, numbness and motor weakness caused by certain types of chemotherapy treatment. Phytocannabinoids are compounds made by the cannabis plant, such as THC and CBD, that have been found to be an effective treatment for chronic pain. Phytocannabinoids may be effective in reducing chronic chemotherapy-induced peripheral neuropathy symptoms in patients treated for breast or colon cancer.",[168,169,30],"Breast Carcinoma","Chemotherapy-Induced Peripheral Neuropathy","2025-12-03",{"date":172,"type":41},"2025-12-05",{"date":174,"type":41},"2025-10-03",{"date":176,"type":21},"2028-01-07",{"name":178,"class":48},"City of Hope Medical Center",2,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":212},"100585216","phase-3-pre-operative-treatment-in-resectable-colon-cancer-100585216","NCT06899477","Pre-Operative Treatment in REseCTable COlon CanceR","Pre-Operative Treatment in REseCTable COlon CanceR (PROTECTOR\u002FFIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, Randomized, Open, Multicenter Phase III Trial to Investigate the Efficacy Preoperative Systemic Therapy in Advanced Colon Cancer","Inclusion Criteria:\n\n1. Patient's signed informed consent.\n2. Patient's age ≥18 years at the time of signing the informed consent.\n3. Histologically confirmed adenocarcinoma of the colon or upper rectum.\n4. Confirmed mismatch-repair proficient and\u002For microsatellite stable tumor. Both Immunohistochemistry and PCR can be used for diagnosis.\n5. Intent for curative surgery\n6. Predicted T3 or T4 stage and or nodal positivity (N+) in a computed tomography and\u002For magnetic resonance imaging scan of the abdomen\u002Fpelvis as assessed by the local study team.\n\n   * T3-4 defined as invasion of surrounding tissue structures or organs\n   * N+ defined as regional lymph node(s) without fat hilus and short axis diameter of ≥1 cm\n7. Absence of clear distant metastases assessed by the investigator based on respective routine evaluations within 6 weeks prior to inclusion into the trial (preferred: computed tomography of thorax and abdomen. Alternatively magnetic resonance images, sonography and x-rays might be used for assessment).\n8. Absence of significant active wound healing including severe chronic non-healing wounds, ulcerous lesions or untreated bone fracture\n9. ECOG performance status 0-2.\n10. Adequate bone marrow, hepatic and renal organ function, defined by the following laboratory test results:\n\n    * Absolute neutrophil count ≥ 1.5 x 109\u002FL (1,500\u002FµL)\n    * Hemoglobin ≥ 80 g\u002FL (8 g\u002FdL) with or without transfusion\n    * Platelet count ≥ 100 x109\u002FL (100,000\u002FµL) without transfusion\n    * Total serum bilirubin of ≤ 1.5 x upper limit of normal (ULN)\n    * Aspartate aminotransferase (AST\u002FGOT) ≤ 3.0 × ULN.\n    * Calculated glomerular filtration rate (GFR) according to Cockcroft-Gault formula or according to MDRD ≥ 50 mL\u002Fmin or serum creatinine ≤ 1.5 x ULN\n11. Patients without anticoagulation need to present with an INR \\\u003C 1.5 x ULN and PTT \\\u003C 1.5 x ULN. Patient with prophylactic or therapeutic anticoagulation are allowed into the trial.\n12. Proficient fluorouracil metabolism as defined:\n\n    1. Prior treatment with 5-FU or capecitabine without unusal toxicity or\n    2. If tested, normal DPD deficiency test according to the standard of the study site or\n    3. If tested, in patients with DPD deficiency test with a CPIC activity score of 1.0-1.5 fluoropyrimidine dosage should be reduced by 50%\n13. For women of childbearing potential (WOCBP): negative pregnancy test within 7 days before treatment initiation and agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of \\\u003C 1% per year during the treatment period and for at least 6 months after the last dose of study treatment.\n\nA woman is considered to be of childbearing potential if she is post-menarcheal, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and\u002For uterus). Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male partner's sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.\n\nFor men: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \\\u003C 1% per year during the treatment period and for 6 months after the last dose of study treatment. Men must refrain from donating sperm during this same period.\n\nWith pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of study medication to avoid exposing the embryo.\n\nExclusion Criteria:\n\n1. Ileus or directly imminent ileus as assessed by the local study team. Patients with treated and resolved ileus are allowed into the trial.\n2. Previous chemotherapy for colorectal cancer of any stage\n3. New York Heart Association Class III or greater heart failure by clinical judgement.\n4. Myocardial infarction within 6 months prior to randomization; percutaneous transluminal coronary angioplasty (PTCA) with or without stenting within 6 months prior to randomization.\n5. Unstable angina pectoris.\n6. Unstable cardiac arrhythmia \\> grade 2 NCI CTCAE despite anti-arrhythmic therapy.\n7. Ongoing toxicities \\> grade 2 NCI CTCAE, in particular peripheral neuropathy.\n8. Active uncontrolled infection by investigator's perspective.\n9. Known hypersensitivity to 5-FU, folinic acid, capecitabine, irinotecan or oxaliplatin or to any of the other excipients listed in section 6.1 of the corresponding SmPC.\n10. Recent or concomitant treatment with brivudine.\n11. Peripheral sensitive neuropathy with functional impairment (\\> grade 1 acc. to CTCAE version 5.0 (see appendix 2)).\n12. Simultaneous application of St. John's Wort preparations.\n13. Pernicious or other megaloblastic anemia caused by vitamin B12 deficiency.\n14. Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to randomization that may interfere with systemic therapy as judged by the investigator.\n15. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications, including but not limited to:\n\n    * Simultaneous application of live vaccines during treatment with irinotecan and for at least 6 months after the last dose.\n    * 5-FU must not be given in combination with brivudin, sorivudin and analogues to patients homozygous for DPD and patients known with completely missing DPD activity.\n    * Severe diarrhoea.\n16. Medical history of malignant disease other than colorectal cancer with the following exceptions:\n\n    * patients who have been disease-free for at least three years before randomization\n    * patients with adequately treated and completely resected basal cell or squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage I uterine cancer\n    * patients with any treated or untreated malignant disease that is associated with a 5-year survival prognosis of ≥ 90% and does not require active therapy\n17. Known alcohol or drug abuse.\n18. Pregnant or breastfeeding females.\n19. Participation in a clinical trial or experimental drug treatment within 28 days prior to potential inclusion in the clinical trial or within a period of 5 half-lives of the substances administered in a clinical trial or during an experimental drug treatment prior to potential inclusion in the clinical trial, depending on which period is longest, or simultaneous participation in another clinical trial while taking part in this clinical trial.\n20. Patients depended on Sponsor, investigator or study site.\n21. Patient committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.\n22. Limited legal capacity","120 Years",{"count":189,"type":21},714,[191],"PHASE3","This is an open-label, randomized, controlled, multicenter, phase III study with two parallel arms. Patients with advanced colon cancer, including the upper third of the rectum, clinically staged cT3-4 and or cN+ (defined as lymph nodes with short axis of at least 1cm) are randomized in a 2:1 fashion (favoring preoperative therapy= Arm A) to investigate the efficacy, patient reported quality of life and safety of preoperative mFOLFOXIRI or mFOLFOX-6 or CAPOX followed by surgery versus the standard of care algorithm (surgery followed by stage-guided adjuvant therapy as recommended by the local multidisciplinary tumor board (Arm B)).",[194,195,30],"Colo-rectal Cancer","Colon Cancer",[197,198,199,200,201],"colo-rectal cancer","colon","neoadjuvant","upper rectum","pre-operative","NOT_YET_RECRUITING","2025-03-21",{"date":205,"type":41},"2025-03-28",{"date":207,"type":21},"2025-04",{"date":209,"type":21},"2035-04",{"name":211,"class":48},"Dominik Paul Modest",28,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":232,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":249},"100565283","phase-2-encorafenib--cetuximab-beyond-progression-in-combination-with-folfiri-in-patients-with-braf-v600e-mutated-metastatic-colorectal-cancer-progressing-on-encorafenib--cetuximab-100565283","NCT06640166","Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.","ECLYPse","Inclusion Criteria:\n\n* written informed consent to study procedures;\n* age ≥ 18 years;\n* histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;\n* radiological evidence of metastatic disease;\n* evidence of measurable disease according to RECIST 1.1 criteria;\n* presence of BRAF V600E mutation in tumor tissue (primary CRC and\u002For related metastasis) as previously determined by a local assay at any time prior to screening (only PCR and NGS-based local assays results will be acceptable);\n* disease progression while on treatment with EC received in 2nd line setting\n\n  * EC administered after disease relapse during treatment or within 6 months following adjuvant therapy will be second line;\n  * maintenance therapy given in the metastatic setting after a first line doublet or triplet chemotherapy will not be considered a separate regimen;\n* best response to previous treatment with EC: CR, PR or SD lasting for at least 3 months.\n* patient fit for a subsequent treatment line with FOLFIRI. Patients exposed to irinotecan and fluoropyrimidines during previous line for metastatic disease are eligible, provided that the patient has recovered from G3 toxicity;\n* life expectancy ≥ 3 months;\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤1.\n* Adequate bone marrow function at screening:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL;\n  * Platelets ≥ 100 × 10\\^9\u002FL;\n  * Hemoglobin ≥ 9.0 g\u002FdL;\n  * Note: Transfusions will be allowed to achieve this. Transfusions will be permitted provided that the patient has not received more than 2 units red blood cells in the prior 4 weeks to achieve this criteria.\n* Adequate renal function at screening: serum creatinine ≤ 1.5 × upper limit of normal (ULN), or calculated by Cockroft-Gault formula, or directly measured creatinine clearance ≥ 50 mL\u002Fmin at screening.\n* Adequate hepatic function at screening:\n\n  * serum total bilirubin ≤ 1.5 × ULN;\n  * alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases.\n* Adequate cardiac function characterized by the following at screening: QT interval corrected for heart rate using Fridericia's formula (QTcF) value ≤480 msec.\n* Availability of treatment-naïve, archival FFPE tumor tissue sample.\n* Ability to take oral medications.\n* Male subjects with female partners of childbearing potential must be willing to use adequate contraception, starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Women of childbearing potential must have a negative blood or urine pregnancy test at the baseline visit.\n* Female subjects of childbearing potential must be willing to use an adequate method of contraception, for the course of the study starting with the first dose of study therapy through 180 days after the last dose of treatment. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n* Will and ability to comply with the protocol.\n\nExclusion Criteria:\n\n* patients experiencing PD as best response to EC;\n* patients with specific BRAFi\u002FAntiEGFR contraindications;\n* patients with specific irinotecan or fluoropyrimidines contraindications;\n* patients with DPYD deficiency;\n* life expectancy ≤3 months;\n* ECOG PS \\>1.\n* Any of the following in the 6 months prior to treatment start: myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft \\[CABG\\], coronary angioplasty or stenting), congestive heart failure (≥ New York Heart Association Classification Class II), serious cardiac arrhythmia (except atrial fibrillation and appropriately controlled paroxysmal supraventricular tachycardia), cerebrovascular accident, symptomatic pulmonary embolism.\n* Congenital long QT syndrome.\n* Impaired gastrointestinal function or disease that may significantly alter the absorption of encorafenib (uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption).\n* Uncontrolled coagulopathy.\n* Patients has a known history of Gilbert's syndrome or is known to have any of the following genotypes: UGT1A1\\*6\u002F\\*6, UGT1A1\\*28\u002F\\*28, or UGT1A1\\*6\u002F\\*28.\n* Active infection requiring systemic therapy.\n* Known history of acute or chronic pancreatitis.\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n* Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).\n* Symptomatic brain metastasis or leptomeningeal disease. Prior hypersensitivity or toxicity that would suggest an inability to tolerate administration of the planned dose of investigational products.\n* Residual CTCAE \\> Grade 2 toxicity from any prior anticancer therapy, with the exception of alopecia or neuropathy.\n* Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies, including current treatment with a non-topical medication known to be a strong inhibitor of cytochrome P450 (CYP) 3A4 ≤ 1 week prior to the start of study treatment.\n* Concomitant use of St. John's Wort (hypericum perforatum).\n* Other severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient an inappropriate candidate for the study.\n* Concurrent or previous other malignancy within the past 3 years, with the exception of effectively treated squamous cell or basal cell skin cancer, melanoma in situ, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, carcinoma in situ of the colon or rectum, or other noninvasive or indolent malignancy without Sponsor approval.\n* Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study and until 180 days after the last trial treatment.",{"count":221,"type":21},25,[60],"The aim of this study is to determine the activity of encorafenib plus cetuximab in combination with FOLFIRI in patients with BRAF V600E mutated metastatic colorectal cancer progressing on encorafenib plus cetuximab administered in second line.",[63,225,226,227,228,229,195,230,30,231],"Colorectal Neoplasms","Colorectal Tumor","Colorectal Adenocarcinoma","Colorectal Cancer (CRC)","Colorectal Cancer","Colon Adenocarcinoma","Colon Neoplasm",[233,234,235,236,237,238,239],"BRAF","V600E","encorafenib","cetuximab","colorectal cancer","FOLFIRI","BRAF V600E","2025-02-11",{"date":242,"type":41},"2025-02-12",{"date":244,"type":41},"2024-06-03",{"date":246,"type":21},"2026-06-30",{"name":248,"class":48},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",3,{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":268,"lastUpdatePostDateStruct":269,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":155},"100436159","lymph-node-mapping-via-flourescent-dye-in-colon-cancer-100436159","NCT04959604","Lymph Node Mapping Via Flourescent Dye in Colon Cancer","Lymph Node Mapping Via the Flourescent Dye ICG in Colon Cancer Through Preoperative Application","Inclusion Criteria:\n\n* histologically diagnosed carcinoma of the ascending, transverse, descending or sigmoid colon.\n\nExclusion Criteria:\n\n* not wanting to participate\n* other carcinoma then adenocarcinoma\n* endoscopic marking not possible","100 Years",{"count":259,"type":21},30,[24],"The aim of the study is to evaluate whether lymph nodes draining the region of the carcinoma are located only inside the lines of standard resection or in some percentages are located outside as well. The visualized nodes draining the region of the carcinoma will be correlated to location, fluorescent yes\u002Fno and nodal positive\u002Fnegative.\n\nThe draining lymph nodes will be visualized using the fluorescent dye indocyanine green.\n\nThe aim of the study is to evaluate whether lymph nodes draining the region of the carcinoma are located only inside the lines of standard resection or in some percentages are located outside as well. The visualized nodes draining the region of the carcinoma will be correlated to location, fluorescent yes\u002Fno and nodal positive\u002Fnegative.\n\nThe draining lymph nodes will be visualized using the fluorescent dye indocyanine green.",[30,263],"Lymph Node Metastases",[265,266,267],"indocyanine green","lymphatic mapping","fluorescence","2023-05-21",{"date":270,"type":41},"2023-05-23",{"date":272,"type":41},"2021-05-31",{"date":274,"type":21},"2026-12-30",{"name":276,"class":48},"Universitätsklinikum Hamburg-Eppendorf"]